Sec. 203. Report to Congress on cancer drug shortages
139 words·~1 min read·
/bill/119/hr/5827/ih/section-203·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, in collaboration with such other agencies as the Secretary deems necessary, shall study the reasons for cancer drug shortages, including— economic reasons; supply chain failures; delays and other complications relating to— the development of cancer drugs; and the approval of such drugs by the Food and Drug Administration; and insufficient generic drugs and biosimilar biological products. Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall complete the study under subsection
(a)and submit a report to the appropriate committees of the Congress on the results of such study. The report under paragraph
(1)shall include recommendations for addressing the reasons for cancer drug shortages.